Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes

Vaccine

Volumn 28, Issue 15, 2010, Pages 2775-2781

  Wu, J ^a   Zhang, F ^a   Fang, F ^a   Chang, H ^a   Wang, F ^b   Yang, Z ^d   Sun, B ^e   Chen, Z ^a,c,d  

^a HUNAN NORMAL UNIVERSITY   (China)

^b Central South University   (China)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

^d SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

^e INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

H5N1; Inactivated vaccine; Influenza; Type 1 diabetes mellitus

Indexed keywords

INACTIVATED VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; INFLUENZA; INFLUENZA VIRUS A H5N1; LD 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; STREPTOZOCIN DIABETES; T LYMPHOCYTE; VIRUS TITRATION; WEIGHT CHANGE;

ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LETHAL DOSE 50; LUNG; MALE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; STREPTOZOCIN; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VIRAL LOAD;

EID: 77649234939     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.037     Document Type: Article

References (32)

1. WHO. Areas with confirmed human cases of H5N1 avian influenza since 2003. http://gamapserver.who.int/mapLibrary/Files/Maps/Global_H5N1inHumanCUMULATIVE_FIMS_20090408.png [accessed 08 April 2009].
2. WHO. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_05_06/en/index.html [accessed 06 May 2009].
3. Webster R.G., Hulse-Post D.J., Sturm-Ramirez K.M., Guan Y., Peiris M., Smith G., et al. Changing epidemiology and ecology of highly pathogenic avian H5N1 influenza viruses. Avian Dis 51 March (Suppl. 1) (2007) 269-272
4. Muller L.M., Gorter K.J., Hak E., Goudzwaard W.L., Schellevis F.G., Hoepelman A.I., et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41 August (3) (2005) 281-288
5. van Riel D., Munster V.J., de Wit E., Rimmelzwaan G.F., Fouchier R.A., Osterhaus A.D., et al. H5N1 virus attachment to lower respiratory tract. Science 312 April (5772) (2006) 399
6. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 March (13) (2006) 1343-1351
7. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 May (9523) (2006) 1657-1664
8. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 February (13-14) (2001) 1732-1737
9. Zhu Q., Chang H., Chen Y., Fang F., Xue C., Zhang F., et al. Protection of inactivated influenza virus vaccine against lethal influenza virus infection in diabetic mice. Biochem Biophys Res Commun 329 April (1) (2005) 87-94
10. Qiu M., Fang F., Chen Y., Wang H., Chen Q., Chang H., et al. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. Biochem Biophys Res Commun 343 May (4) (2006) 1124-1131
11. Zheng L., Wang F., Yang Z., Chen J., Chang H., and Chen Z. A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect Dis 9 (2009) 17
12. Chen Q., Kuang H., Wang H., Fang F., Yang Z., Zhang Z., et al. Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 38 February (1) (2009) 30-38
13. Tamura S.I., Asanuma H., Ito Y., Hirabayashi Y., Suzuki Y., Nagamine T., et al. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 22 February (2) (1992) 477-481
14. WHOc. WHO manual on animal influenza diagnosis and surveillance. http://www.who.int/vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance_2002_5.pdf [accessed May 2002].
15. Drell D.W., and Notkins A.L. Multiple immunological abnormalities in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30 March (3) (1987) 132-143
16. Kaye W.A., Adri M.N., Soeldner J.S., Rabinowe S.L., Kaldany A., Kahn C.R., et al. Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. N Engl J Med 315 October (15) (1986) 920-924
17. Katz S., Klein B., Elian I., Fishman P., and Djaldetti M. Phagocytotic activity of monocytes from diabetic patients. Diabetes Care 6 September-October (5) (1983) 479-482
18. Wismans P.J., van Hattum J., de Gast G.C., Bouter K.P., Diepersloot R.J., Maikoe T., et al. A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. J Med Virol 35 November (3) (1991) 216-222
19. Ficicioglu C., Mikla S., Midilli K., Aydin A., Cam H., and Ergin S. Reduced immune response to hepatitis B vaccine in children with insulin dependent diabetes. Acta Paediatr Jpn 37 December (6) (1995) 687-690
20. Eibl N., Spatz M., Fischer G.F., Mayr W.R., Samstag A., Wolf H.M., et al. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol 103 June (3 Pt 1) (2002) 249-259
21. Pozzilli P., and Leslie R.D. Infections and diabetes: mechanisms and prospects for prevention. Diabet Med 11 December (10) (1994) 935-941
22. Shah B.R., and Hux J.E. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26 February (2) (2003) 510-513
23. Nierkens S., Bleumink R., Bol M., Hassing I., van Rooijen N., and Pieters R. The reactive d-glucopyranose moiety of streptozotocin is responsible for activation of macrophages and subsequent stimulation of CD8+ T cells. Chem Res Toxicol 18 5 (2005) 872-879
24. Reading P.C., Allison J., Crouch E.C., and Anders E.M. Increased susceptibility of diabetic mice to influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose?. J Virol 72 August (8) (1998) 6884-6887
25. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(April (RR-9)):1-25.
26. Estimated influenza vaccination coverage among adults and children-United States, September 1-November 30, 2004. MMWR Morb Mortal Wkly Rep 2004;53(December (49)):1147-53.
27. el-Madhun A.S., Cox R.J., Seime A., Sovik O., and Haaheim L.R. Systemic and local immune responses after parenteral influenza vaccination in juvenile diabetic patients and healthy controls: results from a pilot study. Vaccine 16 January-February (2-3) (1998) 156-160
28. Diepersloot R.J., Bouter K.P., Beyer W.E., Hoekstra J.B., and Masurel N. Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologia 30 June (6) (1987) 397-401
29. Hiltunen M., Hyoty H., Leinikki P., Akerblom H.K., Tuomilehto J., and Vesikari T. Low mumps antibody levels induced by mumps-measles-rubella vaccinations in type 1 diabetic children. Diabet Med 11 December (10) (1994) 942-946
30. Colquhoun A.J., Nicholson K.G., Botha J.L., and Raymond N.T. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 119 December (3) (1997) 335-341
31. Hak E., Nordin J., Wei F., Mullooly J., Poblete S., Strikas R., et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 35 August (4) (2002) 370-377
32. Heymann A.D., Shapiro Y., Chodick G., Shalev V., Kokia E., Kramer E., et al. Reduced hospitalizations and death associated with influenza vaccination among patients with and without diabetes. Diabetes Care 27 November (11) (2004) 2581-2584